Supporting tomorrow’s medical leaders
We’re committed to empowering physicians to succeed
The GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surfaceª delivers durable performance in SFA to enhance the endovascular treatment journey and support patient care.1,2
> 3,300
scientific publicationsb
> 8,650
implant facilities using the VIABAHN® Device3
> 1,700,000
devices implanted in patients worldwidec,3
You rely on a partner you can trust
Our supply chain ensures timely delivery, so you can focus on patient care
> 99.9%
of orders are accurately fulfilled and shipped the same dayd
70%
saving in ordering time and processing costse,3
Ready for reliable long-term performance with the VIABAHN® Device?
The VIABAHN® Device has become a valuable device for physicians' challenging SFA procedures.
Value of the VIABAHN® Device
How could the VIABAHN® Device support your complex SFA procedures?
a. As used by Gore, PROPATEN Bioactive Surface refers to Gore's proprietary CBAS® Heparin Surface.
b. Data shown is representative of all generations of the VIABAHN® Device.
c. Data reflects all generations of the VIABAHN® Device.
d. Based on data retrieved over a period of 2 years.
e. Based on the specialty literature around order processing costs our assumption for time saving from manual to EDI order creation and placement is 70%.
- Ilda O, Ohki T, Soga Y, et al. Five-year outcomes of the GORE® VIABAHN® Endoprosthesis for the treatment of complex femoropopliteal lesions from a Japanese postmarket surveillance study. Vascular Medicine 2024;29(4):416-423.
- Bosiers M, Deloose K, Callaert J, et al. Stent-grafts are the best way to treat complex in-stent restenosis lesions in the superficial femoral artery: 24-month results from a multicenter randomized trial, The Journal of Cardiovascular Surgery 2020;61(5):617-625.
- Data on file 2025; W. L. Gore & Associates, Inc; Flagstaff, AZ.
Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly
INDICATIONS FOR USE IN EUROPE: The GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface is indicated for the treatment of:
- de novo or restenotic lesions in the iliac arteries
- de novo or restenotic lesions in the superficial femoral artery and proximal popliteal artery
- in-stent restenotic lesions in the superficial femoral artery and proximal popliteal artery
- stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous (AV) access grafts and in the venous outflow of dialysis access circuits, including the central veins
- popliteal artery aneurysms and isolated visceral artery aneurysms
- traumatic or iatrogenic vessel injuries in arteries that are located in the chest cavity, abdominal cavity or pelvis (except for aorta, coronary, innominate, carotid, vertebral and pulmonary arteries)
CONTRAINDICATIONS:
- Non-compliant lesions where full expansion of an angioplasty balloon catheter was not achieved during pre-dilatation, or where lesions cannot be dilated sufficiently to allow passage of the delivery system.
- Do not use the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface in patients with known hypersensitivity to heparin, including those patients who have had a previous incidence of Heparin-Induced Thrombocytopenia (HIT) type II.